We encountered an unexpected error, we encourage you to try again later.
Should you have additional questions please contact PfizerPro customer service.
Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time
Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.
To gain access please enter your professional information within your account.
Should you need further support updating your account information, please contact PfizerPro customer service.
Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time
Should you have additional questions please contact PfizerPro customer service.
Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time
All samples available online to you are included below. Availability is updated periodically.
Savings cards will be shipped with Product Samples, if applicable.
Use your mouse, finger, or stylus to sign below.
I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.
We have received your order and are getting it ready
Download available co-pay cards and patient savings offers across select Pfizer products.
Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.
Changes you have made will not be saved.
Menu
Menu
Phase 3 Study: Primary Endpoints
Phase 3 Study: Secondary and Other Endpoints
Steroid-free EUCRISA provides efficacy and can be used as part of a long-term treatment plan1,2
EUCRISA has a dosing regimen that can be adjusted to fit your patient’s needs1
EUCRISA has safety data across 5 studies, including pivotal and Open-Label Safety Extension Studies, and an Open-Label Infant Safety Study1,3
EUCRISA is now FDA-approved with an expanded dosing recommendation to consider once-daily application once clinical effect has been achieved with twice-daily application1
EUCRISA is now
FDA-approved with an expanded dosing recommendation to consider once-daily application once clinical effect has been achieved with twice-daily application1
EUCRISA is now
FDA-approved with an expanded dosing recommendation to consider once-daily application once clinical effect has been achieved with twice-daily application1
Register or sign in to check availability and request samples
Register or sign in to check availability and request samples
Learn more about a 28-day, single-arm, open-label study in 3 to <24-month-old patients2
*Eligible patients pay as little as $10
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2026 Pfizer Inc. All rights reserved.
EUCRISA (crisaborole) is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.